Cannabis Science Inc (OTCMKTS:CBIS) recently announced that the initial test batch of CBIS metered dose inhalers or MDI has been sold out completely by the California distributors. This was the company’s test market run in California. On account of increased demand of these inhalers, the company has also increased production, in anticipation of high consumer demand.
Higher demand for CBIS Metered Dose Inhalers
The CEO of company, Mr. Raymond C. Dabney, in the recent press release stated, “We did not expect demand for our Inhaler to increase so rapidly.” He added that this was not the company’s large initial test batch, but its pilot program has indicated towards “great success considering the application and target market.”
In response to the demand, the Cannabis Science Inc has enhanced production with the present manufacturer it is working with. Mr. Raymond C. Dabney, in this regard said, “We are identifying and implementing key manufacturing and distribution expansions to ensure we meet the growing demand for the CBIS MDI Inhaler.”
California and the legal Cannabis channels
In the U.S., California is known to be the most populous state. In fact, it has sixth-largest economy of the world and the state alone enjoys a GDP of $2.5 trillion. The company believes that the revenue streams of this company in California will tap open; especially with the state consenting to the legal cannabis channels.
There is a huge demand for the CBIS products due to the surrounding geographical terrain. In view of legal market, Cannabis Science Inc has a huge potential to explore; especially when it comes to the industry.
Read more ...
According to the Office of National Drug Control Policy, since 1996, 23 states and Washington, DC have passed laws allowing marijuana use for a variety of medical conditions. Of course, these state laws do not change the actuality that using marijuana is an offense under federal law. Nor do these state marijuana laws change the criteria or process for FDA approval of safe and effective medications.
In response to California’s Proposition 215, the Institute of Medicine issued a report that examined potential therapeutic uses for marijuana. The report found that:
“Scientific data indicate the potential therapeutic value of cannabinoid drugs, primarily THC, for pain relief; control of nausea and vomiting; and appetite stimulation; smoked marijuana, however, is a crude THC delivery system that also delivers harmful substances.”
Now prescribing and monitoring the medicinal marijuana has become more adept. Syqe Medical, a startup out of Tel-Aviv, Israel has designed a cannabis inhaler. In other words, Syqe Inhaler is a pocket-sized selective-dose drug delivery platform which will allow patients regain quality of life.
This inhaler utilizes selective 100 microgram dosing precision, real-time thermal and flow controllers, lung interfacing, and wireless connectivity.
Israel’s Ministry of Health approved the inhaler and it has been in use for a year at Rambam Medical Center in the city of Haifa. Times of Israel describes the institution as the world’s first of its kind to prescribe weed as “standard medical treatment.”
“The company has completed clinical trials demonstrating the inhaler’s precision and compliance with pharmaceutical standards.
Read more ...